Novartis data confirm rapid response and high efficacy of Cosentyx ® in psoriasis patients for first time in China

Novartis announced today new data in 441 Chinese patients with moderate to severe plaque psoriasis from a Phase III study investigating the efficacy and safety of Cosentyx (secukinumab). The data, part of a broader ongoing 52 week Phase III study in 543 patients, show 97.7% of patients treated with Cosentyx 300mg achieved PASI 75 and 80.9% achieved PASI 90 by week 12, with 87% of patients reaching PASI 90 by week 16.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news